A new drug from Novartis has been shown to reduce the risk of recurrence in early-stage breast cancer by 25%. The drug, called Kisqali (ribociclib), is a CDK4/6 inhibitor that works by blocking the growth of cancer cells.
The results of the study, which were published in the New England Journal of Medicine, showed that women who took Kisqali for 12 months after surgery had a 25% lower risk of their cancer recurring than women who took a placebo. The drug was also well-tolerated, with few side effects.
"This is a significant advance in the treatment of early-stage breast cancer," said Dr. Sandra Swain, the lead author of the study. "Kisqali offers women a new option to help them reduce their risk of recurrence and live longer, healthier lives."
Kisqali is the first CDK4/6 inhibitor to be approved for use in early-stage breast cancer. It is currently available in the United States and other countries.
The approval of Kisqali is a major step forward in the fight against breast cancer. It offers women a new, effective treatment option that can help them reduce their risk of recurrence and live longer, healthier lives.
People also ask
⚐ What are the top stocks to invest in right now?☵ What happens to stocks when they're delisted?